Publications by authors named "S Penning"

In bacteria the formation of disulphide bonds is facilitated by a family of enzymes known as the disulphide bond forming (Dsb) proteins, which, despite low sequence homology, belong to the thioredoxin (TRX) superfamily. Among these enzymes is the disulphide bond-forming protein A (DsbA); a periplasmic thiol oxidase responsible for catalysing the oxidative folding of numerous cell envelope and secreted proteins. Pathogenic bacteria often contain diverse Dsb proteins with distinct functionalities commonly associated with pathogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • Aptasensors detect biomolecules by transforming the binding of specific target molecules with aptamers into measurable signals, helping in rapid biomolecule identification.
  • The study compares different crosslinkers used for immobilizing aptamers, focusing on one homo-bifunctional and three hetero-bifunctional types, specifically for attaching the Ebola soluble Glycoprotein (sGP) binding DNA aptamer to surfaces.
  • Results indicate that using hetero-bifunctional crosslinkers leads to more consistent sensing responses and higher aptamer densities compared to homo-bifunctional crosslinkers, which produced inconsistent responses and lower attachment efficiency.
View Article and Find Full Text PDF

Background: Elevated blood glucose (BG) concentrations (Hyperglycaemia) are a common complication in critically ill patients. Insulin therapy is commonly used to treat hyperglycaemia, but metabolic variability often results in poor BG control and low BG (hypoglycaemia).

Objective: This paper presents a model-based virtual trial method for glycaemic control protocol design, and evaluates its generalisability across different populations.

View Article and Find Full Text PDF

So far, among the different non-invasive neurostimulation methods, only transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly (Cefaly Technology sprl, Herstal, Belgium) device has randomized controlled trial-based evidence for safety and efficacy and obtained American Food and Drug Administration approval for the prevention of episodic migraine. In a double-blinded, randomized, sham-controlled trial on 67 episodic migraine patients (mean pre-treatment migraine days/month: 6.9), the 50% responder rate after 3 months was significantly higher in the active group (38.

View Article and Find Full Text PDF